Legend Biotech Corp reports results for the quarter ended March 31 - Earnings Summary

• Legend Biotech Corp LEGN.OQ reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 23 cents per share. Wall Street expected results to range from -42 cents to -13 cents per share.

• Revenue rose 107.5% to $195.05 million from a year ago; analysts expected $193.62 million.

• Legend Biotech Corp's reported EPS for the quarter was a loss of 54 cents​.

• The company reported a quarterly loss of $100.92 million.

• Legend Biotech Corp shares had fallen by 4.6% this quarter and lost 0.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 28.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Legend Biotech Corp is $80.00

This summary was machine generated from LSEG data May 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)